Advanced Malignancies

12
Pipeline Programs
10
Companies
28
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
7
3
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
150%
Monoclonal Antibody
150%
+ 10 programs with unclassified modality

Competitive Landscape

10 companies ranked by most advanced pipeline stage

BeOne Medicines
BeOne MedicinesCA - San Carlos
1 program
1
TislelizumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT04164199Enrolling By InvitationEst. Dec 2026
Bristol Myers Squibb
1 program
1
TanespimycinPhase 24 trials
Active Trials
NCT00546780Completed31Est. Mar 2010
NCT00514371Completed22Est. Feb 2009
NCT00779428Completed6Est. Jul 2013
+1 more trials
Astellas
AstellasChina - Shenyang
2 programs
1
1
ASP7517Phase 1/21 trial
ASP3026Phase 11 trial
Active Trials
NCT01284192Completed46Est. Mar 2016
NCT04837196Completed24Est. Jun 2024
BioInvent International
1 program
1
BI-1808Phase 1/21 trial
Active Trials
NCT04752826Recruiting176Est. Jan 2028
Celldex Therapeutics
1 program
1
CDX-1401 in combination with Resiquimod and/or Poly-ICLCPhase 1/21 trial
Active Trials
NCT00948961Completed70Est. Feb 2014
Novartis
NovartisBASEL, Switzerland
2 programs
2
PDR001Phase 11 trial
PatupilonePhase 15 trials
Active Trials
NCT02678260Completed18Est. Sep 2017
NCT00496600Completed42Est. Feb 2011
NCT00442741Withdrawn0
+3 more trials
Elevar Therapeutics
Elevar TherapeuticsKorea - Seoul
1 program
1
ApatinibPhase 1Small Molecule1 trial
Active Trials
NCT03407976Terminated5Est. Jul 2020
Regeneron
RegeneronTARRYTOWN, NY
1 program
1
REGN2810Phase 11 trial
Active Trials
NCT02520245Withdrawn0Est. Nov 2023
CT
1 program
1
TQB3455Phase 11 trial
Active Trials
NCT04340427UnknownEst. Dec 2021
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
1
WX-UK1 in combination with CapecitabinePhase 11 trial
Active Trials
NCT00083525Completed33

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
BeOne MedicinesTislelizumab
Bristol Myers SquibbTanespimycin
NovartisPatupilone
Bristol Myers SquibbTanespimycin
NovartisPatupilone
Bristol Myers SquibbTanespimycin
NovartisPatupilone
NovartisPatupilone
AstellasASP7517
BioInvent InternationalBI-1808
Celldex TherapeuticsCDX-1401 in combination with Resiquimod and/or Poly-ICLC
Bristol Myers SquibbTanespimycin
Chia Tai TianQing Pharmaceutical GroupTQB3455
Elevar TherapeuticsApatinib
NovartisPDR001

Showing 15 of 28 trials with date data

Clinical Trials (28)

Total enrollment: 1,794 patients across 28 trials

NCT04164199BeOne MedicinesTislelizumab

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Start: Dec 2019Est. completion: Dec 2026
Phase 3Enrolling By Invitation
NCT00546780Bristol Myers SquibbTanespimycin

A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse

Start: Feb 2008Est. completion: Mar 201031 patients
Phase 3Completed
NCT00262990NovartisPatupilone

Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer

Start: Nov 2005829 patients
Phase 3Completed
NCT00514371Bristol Myers SquibbTanespimycin

A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma

Start: Aug 2007Est. completion: Feb 200922 patients
Phase 2/3Completed
NCT00411528NovartisPatupilone

Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

Start: Sep 2006Est. completion: Sep 2012185 patients
Phase 2Completed
NCT00779428Bristol Myers SquibbTanespimycin

Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin

Start: Jul 2006Est. completion: Jul 20136 patients
Phase 2Completed
NCT00273312NovartisPatupilone

Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma

Start: Jan 200625 patients
Phase 2Completed
NCT00219297NovartisPatupilone

Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer

Start: Nov 2005Est. completion: Jun 201050 patients
Phase 2Completed
NCT04837196AstellasASP7517

Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen

Start: Nov 2021Est. completion: Jun 202424 patients
Phase 1/2Completed
NCT04752826BioInvent InternationalBI-1808

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

Start: Jan 2021Est. completion: Jan 2028176 patients
Phase 1/2Recruiting
NCT00948961Celldex TherapeuticsCDX-1401 in combination with Resiquimod and/or Poly-ICLC

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Start: Sep 2009Est. completion: Feb 201470 patients
Phase 1/2Completed
NCT00773344Bristol Myers SquibbTanespimycin

Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin

Start: Dec 2005Est. completion: Aug 200925 patients
Phase 1/2Completed
NCT04340427Chia Tai TianQing Pharmaceutical GroupTQB3455

A Study of TQB3455 Tablets in Subjects With Advanced Malignancies

Start: Apr 2020Est. completion: Dec 2021
Phase 1Unknown
NCT03407976Elevar TherapeuticsApatinib

Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies

Start: Jun 2018Est. completion: Jul 20205 patients
Phase 1Terminated
NCT02678260NovartisPDR001

Phase I Study of PDR001 in Patients With Advanced Malignancies.

Start: Feb 2016Est. completion: Sep 201718 patients
Phase 1Completed
NCT02520245RegeneronREGN2810

Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study

Start: Aug 2015Est. completion: Nov 20230
Phase 1Withdrawn
NCT01284192AstellasASP3026

Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)

Start: Dec 2010Est. completion: Mar 201646 patients
Phase 1Completed
NCT00442741NovartisPatupilone

Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies (Extension)

Start: Jul 20070
Phase 1Withdrawn
NCT00496600NovartisPatupilone

Phase I Study of Patupilone and RAD001

Start: Jul 2007Est. completion: Feb 201142 patients
Phase 1Completed
NCT00468260NovartisPatupilone

The Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies

Start: May 200712 patients
Phase 1Terminated
NCT00448396NovartisPatupilone

Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies

Start: Mar 200717 patients
Phase 1Completed
NCT00426140NovartisPatupilone

Pharmacokinetics of Patupilone After a Single Intravenous Administration in Patients With Advance Solid Tumor Malignancies.

Start: Aug 20065 patients
Phase 1Completed
NCT00412789NovartisPatupilone

Efficacy and Safety of Patupilone in Patients With Advanced Solid Tumors in Japan

Start: Aug 200615 patients
Phase 1Completed
NCT00426582NovartisPatupilone

Combination Trial of Patupilone and Carboplatin in Adult Patients With Advanced Solid Tumors

Start: Aug 200648 patients
Phase 1Completed
NCT00421044NovartisPatupilone

A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function

Start: May 200614 patients
Phase 1Completed
NCT00420524NovartisPatupilone

A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function

Start: Jan 200636 patients
Phase 1Completed
NCT00083525Heidelberg PharmaWX-UK1 in combination with Capecitabine

Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies

Start: May 200433 patients
Phase 1Completed
NCT00969046NovartisPatupilone

Dose-Escalation Study in Advanced Colon Cancer Patients

Start: Nov 2003Est. completion: Nov 200660 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 1,794 patients
10 companies competing in this space